Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-line treatment for patients with hypertension: An ALLHAT analysis

被引：0
|
作者：
Heidenreich, PA
Davis, BR
Furberg, CD
Lairson, DR
Pressel, S
Goldman, L
机构：
[1] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2006年 / 47卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：372A / 372A
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Paul A. Heidenreich
    Barry R. Davis
    Jeffrey A. Cutler
    Curt D. Furberg
    David R. Lairson
    Michael G. Shlipak
    Sara L. Pressel
    Chuke Nwachuku
    Lee Goldman
    Journal of General Internal Medicine, 2008, 23 : 509 - 516
  • [2] Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: An analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Heidenreich, Paul A.
    Davis, Barry R.
    Cutler, Jeffrey A.
    Furberg, Curt D.
    Lairson, David R.
    Shlipak, Michael G.
    Pressel, Sara L.
    Nwachuku, Chuke
    Goldman, Lee
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2008, 23 (05) : 509 - 516
  • [3] Cost-effectiveness analysis of first-line HAART
    Maggiolo, F.
    Di Matteo, S.
    Masini, G.
    Astuti, N.
    Di Filippo, E.
    Bernardini, C.
    Soavi, L.
    Colombo, G.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2012, 15 : 69 - 70
  • [4] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Jonathan P. Shepherd
    Charelle M. Carter-Brooks
    Christopher Chermanksy
    International Urogynecology Journal, 2018, 29 : 1213 - 1219
  • [5] A Cost-Effectiveness Analysis of Onabotulinumtoxin A as First-Line Treatment for Overactive Bladder
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2018, 73 (11) : 629 - 630
  • [6] A cost-effectiveness analysis of Onabotulinumtoxin A as first-line treatment for overactive bladder
    Shepherd, Jonathan P.
    Carter-Brooks, Charelle M.
    Chermanksy, Christopher
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1213 - 1219
  • [7] THE COST-EFFECTIVENESS OF CATHETER ABLATION AS FIRST-LINE TREATMENT
    Aronsson, M.
    Walfridsson, H.
    Janzon, M.
    Walfridsson, U.
    Levin, L. A.
    VALUE IN HEALTH, 2013, 16 (07) : A529 - A529
  • [8] Cost-effectiveness of olanzapine as a first-line treatment: A comment
    Basu, Anirban
    VALUE IN HEALTH, 2006, 9 (05) : 357 - 357
  • [9] Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
    Abdelmageed Abdelrahman
    International Urogynecology Journal, 2018, 29 : 1221 - 1221
  • [10] Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder
    Abdelrahman, Abdelmageed
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2018, 29 (08) : 1221 - 1221
12345